Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate progression free survival in those participants
assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus
Best Supportive Care in Advanced Neuroendocrine Tumors of pancreatic origin.